COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Shareholders' equity fell to $2.945 million at June 30, 2026, from $6.081 million at December 31, 2025.

Rhea-AI Summary

CollPlant Biotechnologies (CLGN) reported second-quarter 2026 revenue of $108,000 and a narrower net loss, alongside its completed acquisition of LightSolver. Revenue fell from $179,000 a year earlier. Net loss narrowed to $2.726 million, or $1.89 per share, from $3.347 million, or $2.83 per share. Operating expenses fell to $2.177 million from $3.171 million, while gross loss widened to $456,000 from $7,000.

First-half revenue fell to $181,000 from $2.234 million, and net loss widened to $5.823 million from $4.799 million. June 30 cash was $2.559 million; first-half operating cash use was $5.382 million. After June 30, CollPlant received $1.94 million in remaining gross private-placement proceeds and approximately $5.2 million from warrant exercises. The September acquisition adds laser-based photonic computing to its regenerative medicine business; LightSolver operations are excluded from the reported periods.

11 points · 3 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

2 major · 13 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointFebruary 2026 issuance of shares and warrants raised $1.719 million net. 24% of market cap
• Major pointJune private-placement securities generated $620,000 net before June 30; completion on July 6 brought $1.94 million remaining gross proceeds. 27% of market cap
• Major pointAugust and September warrant exercises generated approximately $5.2 million in aggregate proceeds. 73% of market cap
• Moderate pointThe completed September 2026 LightSolver acquisition adds a photonic computing business to CollPlant's technology portfolio.
• Moderate pointSecond-quarter GAAP net loss narrowed to $2.726 million from $3.347 million; loss per share fell to $1.89 from $2.83.
• Moderate pointSecond-quarter GAAP operating expenses fell to $2.177 million from $3.171 million a year earlier.

5 minor points

• Minor pointFirst-half GAAP operating expenses fell to $5.049 million from $6.686 million a year earlier.
• Minor pointSecond-quarter net financial expenses fell to $93,000 from $169,000 a year earlier.
• Minor pointFirst-half investing cash flow improved to $8,000 provided from $11,000 used a year earlier.
• Minor pointTotal liabilities fell to $4.252 million at June 30, 2026, from $4.704 million at December 31, 2025.
• Minor point. Forward-looking: it has not happened yet and may not happen.CollPlant continues advancing its plant-derived rhCollagen platform and pursuing medical-aesthetics and tissue-bioprinting partnerships.

Negative

• Major pointOrdinary shares outstanding increased to 1,444,350 at June 30 from 1,280,301 at December 31, on a split-adjusted basis.
• Major pointExercises of Series B warrants and pre-funded warrants in August and September issued additional shares.
• Moderate pointFirst-half revenue fell to $181,000 from $2.234 million; a $2.0 million development milestone payment did not recur.
• Moderate pointFirst-half gross loss was $699,000, versus gross profit of $1.860 million a year earlier.
• Moderate pointFirst-half operating cash use increased to $5.382 million from $3.607 million a year earlier.
• Moderate pointCash fell to $2.559 million at June 30, 2026, from $5.591 million at December 31, 2025.
• Moderate pointShareholders' equity fell to $2.945 million at June 30, 2026, from $6.081 million at December 31, 2025.

6 minor points

• Minor pointSecond-quarter revenue fell to $108,000 from $179,000 a year earlier, primarily reflecting lower rhCollagen-based product sales.
• Minor pointSecond-quarter gross loss widened to $456,000 from $7,000 a year earlier.
• Minor pointSecond-quarter cost of revenues rose to $564,000 from $186,000 a year earlier.
• Minor pointFirst-half cost of revenues rose to $880,000 from $374,000, reflecting lower facility utilization and inventory write-downs.
• Minor pointFirst-half GAAP net loss widened to $5.823 million from $4.799 million; loss per share rose to $4.13 from $4.12.
• Minor pointFirst-half net financial expenses were $75,000, versus $27,000 net financial income a year earlier.

News Explained

The CEO describes the HLRS study as showing acceleration of up to 80,000 times; the release’s detailed account specifies projected time-to-solution acceleration from approximately 40 times to more than 80,000 times versus GPU algorithms, depending on the benchmark and algorithm.

Key Figures

Q2 GAAP revenue: $108,000 vs. $179,000 Six-month GAAP revenue: $181,000 vs. $2.2 million Q2 GAAP net loss: $2.7 million vs. $3.3 million +5 more

Q2 GAAP revenue

$108,000 vs. $179,000

Three months ended June 30, 2026 vs. 2025

Six-month GAAP revenue

$181,000 vs. $2.2 million

Six months ended June 30, 2026 vs. 2025

Q2 GAAP net loss

$2.7 million vs. $3.3 million

Three months ended June 30, 2026 vs. 2025

Six-month GAAP net loss

$5.8 million vs. $4.8 million

Six months ended June 30, 2026 vs. 2025

Cash and cash equivalents

$2.6 million

As of June 30, 2026

Cash used in operating activities

$5.4 million vs. $3.6 million

Six months ended June 30, 2026 vs. 2025

Private placement proceeds

$1.94 million gross proceeds

Received after the placement was completed on July 6, 2026

Warrant exercise proceeds

Approximately $5.2 million

Aggregate proceeds during August and September 2026

Previous Earnings Reports

2 past events · Latest: May 29

Same Type 2 events

1. May 29

   Q1 earnings

   24h Move

   -0.7%

   Reported Q1 2026 revenue of $73,000 and net loss of $3.1 million.

2. Aug 20

   Q2 earnings

   24h Move

   -20.2%

   Reported Q2 revenue of $179,000 and net loss of $3.3 million, the year-ago comparator.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gaap, non-gaap, high-performance computing (hpc), registered direct offering, +1 more

5 terms

gaap financial

"GAAP revenues for the second quarter ended June 30, 2026"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

non-gaap financial

"On a non-GAAP basis, operating expenses for the second quarter"

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

high-performance computing (hpc) technical

"entry into high-performance computing (HPC) and photonics computing markets"

High-performance computing (HPC) involves using powerful computers to process complex data and run large-scale calculations much faster than regular computers. It helps organizations solve challenging problems, such as predicting market trends or analyzing scientific data, enabling quicker decision-making. For investors, HPC can highlight advancements in technology and innovation that may impact various industries and market opportunities.

registered direct offering financial

"$1.7 million of net proceeds from the February 2026 registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"net proceeds received on account of securities to be issued under the June 2026 private placement"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine

REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), today announced financial results for the second quarter of 2026 and provided a corporate update.

Yehiel Tal, CollPlant's Chief Executive Officer, commented: "The acquisition of LightSolver marks CollPlant's strategic entry into high-performance computing (HPC) and photonics computing markets, alongside our regenerative medicine activities. LightSolver's pioneering LPU technology, recently validated in a peer-reviewed study with Germany's HLRS demonstrating acceleration of fundamental HPC workloads by up to 80,000 times, provides an exciting opportunity to diversify our portfolio and create long-term shareholder value. We are also pleased to welcome LightSolver co-founder Dr. Ruti Ben Shlomi to our Board, bringing deep scientific and entrepreneurial expertise as we advance the technology toward commercialization."

Mr. Tal continued, "Concurrently, we remain committed to our leadership in regenerative medicine. We are actively advancing our proprietary plant-derived rhCollagen platform and continue to dedicate significant resources toward establishing strategic partnerships with leading global players to utilize our technology in medical aesthetics and 3D bioprinting of tissues and organs."

Second Quarter and Recent Highlights

• Completed the Acquisition of LightSolver: In September 2026, CollPlant completed the acquisition of LightSolver, a pioneer in laser-based pure photonic computing. This transaction positions LightSolver to accelerate the commercialization of its Laser Processing Unit (LPU) as a new computing layer alongside CPU's and GPU's.
• Significant HPC Acceleration Demonstrated: Joint research by LightSolver and the High-Performance Computing Center Stuttgart (HLRS) published in the ACM proceedings demonstrated projected time-to-solution acceleration ranging from approximately  40× to more than 80,000× compared with state-of-the-art GPU-based algorithms, depending on the benchmark problem and algorithm evaluated.
• Board of Directors Appointment: Following the closing of the acquisition, CollPlant appointed Dr. Ruti Ben Shlomi, CEO and Co-Founder of LightSolver, to its Board of Directors to support the group's diversified commercial and technological roadmap.

Because the acquisition of LightSolver was signed and completed after June 30, 2026, the financial results presented below for the three and six months ended June 30, 2026 do not include the results of operations of LightSolver.

Three and Six Month-Period Ended June 30, 2026 Financial Results

GAAP revenues for the second quarter ended June 30, 2026, were $108,000 compared to $179,000 for the second quarter ended June 30, 2025. The decrease was primarily attributable to lower sales of rhCollagen-based products.

GAAP revenues for the six months ended June 30, 2026, were $181,000 compared to $2.2 million for the six months ended June 30, 2025. The decrease was primarily attributable to a $2.0 million development milestone payment from a former business collaborator recognized as revenue in 2025, which did not recur in 2026.

GAAP cost of revenues for the three and six months ended June 30, 2026, was $564,000 and $880,000, respectively, compared to $186,000 and $374,000 for the three and six months ended June 30, 2025, respectively. The increase of approximately $378,000 and $506,000 for the three and six-month periods, respectively, was mainly attributable to lower utilization of production facilities and inventory write-downs recorded during the period.

GAAP gross loss for the second quarter ended June 30, 2026, was $456,000, compared to a gross loss of $7,000 in the second quarter ended June 30, 2025.

GAAP gross loss for the six months ended June 30, 2026, was $699,000, compared to gross profit of $1.9 million in the six months ended June 30, 2025.

GAAP operating expenses for the second quarter ended June 30, 2026, were $2.2 million, compared to $3.2 million in the second quarter ended June 30, 2025. The decrease of approximately $1.0 million was mainly related to the Company's cost reduction plan, including (i) a $500,000 decrease in personnel-related and share-based compensation expenses, (ii) a $263,000 decrease in manufacturing and facility-related costs allocated to research and development as a result of reduced development activity, and (iii) a $177,000 decrease in professional service expenses within general and administrative expenses. On a non-GAAP basis, operating expenses for the second quarter ended June 30, 2026, were $2.1 million compared to $2.8 million for the second quarter ended June 30, 2025. Non-GAAP measures exclude certain non-cash expenses.

GAAP operating expenses for the six months ended June 30, 2026, were $5.0 million, compared to $6.7 million in the six months ended June 30, 2025. The decrease of approximately $1.6 million was mainly related to the Company's cost reduction plan, including (i) a $504,000 decrease in personnel-related and share-based compensation expenses, (ii) a $331,000 decrease in manufacturing and facility-related costs allocated to research and development, (iii) a $217,000 decrease in research and development expenses related to the breast implant project, and (iv) a $300,000 decrease in professional service expenses. On a non-GAAP basis, operating expenses for the six months ended June 30, 2026, were $4.8 million compared to $6.0 million for the six months ended June 30, 2025. Non-GAAP measures exclude certain non-cash expenses.

GAAP financial expenses, net, for the second quarter ended June 30, 2026, totaled $93,000, compared to financial expenses, net, of $169,000 in the second quarter ended June 30, 2025. The decrease was primarily related to exchange rate differences.

GAAP financial expenses, net, for the six months ended June 30, 2026, totaled $75,000, compared to financial income, net, of $27,000 in the six months ended June 30, 2025. The change was mainly related to lower interest income on short-term cash deposits.

GAAP net loss for the second quarter ended June 30, 2026, was $2.7 million, or $1.89 basic loss per share, compared to a net loss of $3.3 million, or $2.83 basic loss per share, for the second quarter ended June 30, 2025. Non-GAAP net loss for the second quarter ended June 30, 2026, was $2.4 million, or $1.69 basic loss per share, compared to a non-GAAP net loss of $2.7 million, or $2.30 basic loss per share, for the second quarter ended June 30, 2025.

GAAP net loss for the six months ended June 30, 2026, was $5.8 million, or $4.13 basic loss per share, compared to a net loss of $4.8 million, or $4.12 basic loss per share, for the six months ended June 30, 2025. Non-GAAP net loss for the six months ended June 30, 2026, was $5.4 million, or $3.81 basic loss per share, compared to a non-GAAP net loss of $3.9 million, or $3.31 basic loss per share, for the six months ended June 30, 2025.

Balance Sheet and Cash Flow

Cash and cash equivalents as of June 30, 2026, were $2.6 million.

Cash used in operating activities during the six months ended June 30, 2026, was $5.4 million compared to $3.6 million during the six months ended June 30, 2025. The increase primarily reflects the $2.0 million development milestone payment received in the first quarter of 2025 that did not recur in 2026, partially offset by the Company's cost reduction measures.

Cash provided by investing activities during the six months ended June 30, 2026, was $8,000 compared to cash used in investing activities of $11,000 during the six months ended June 30, 2025. Cash provided by investing activities in 2026 was primarily attributable to $83,000 of proceeds from the sale of property and equipment, partially offset by $75,000 of purchases of property and equipment.

Cash provided by financing activities during the six months ended June 30, 2026, was $2.3 million compared to $3.1 million during the six months ended June 30, 2025. Cash provided by financing activities in 2026 consisted of $1.7 million of net proceeds from the February 2026 registered direct offering and $0.6 million of net proceeds received on account of securities to be issued under the June 2026 private placement. Subsequent to June 30, 2026, the private placement was completed on July 6, 2026, and the Company received the remaining $1.94 million of gross proceeds. In addition, during August and September 2026, certain shareholders exercised Series B warrants and pre-funded warrants, resulting in aggregate proceeds to the Company of approximately $5.2 million.

 

 

COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands)
		June 30,				December 31,
		2026				2025
		Unaudited
Assets
Current assets:
Cash and cash equivalents		$	2,559			$	5,591
Restricted deposit			392				359
Trade receivables, net			16				1
Inventories			540				573
Other accounts receivable and prepaid expenses			389				223
Total current assets			3,896				6,747
Non-current assets:
Restricted deposit			83				76
Operating lease right-of-use assets			2,127				2,426
Property and equipment, net			1,046				1,463
Intangible assets, net			45				73
Total non-current assets			3,301				4,038
Total assets		$	7,197			$	10,785

 

 

COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share data)
		June 30,				December 31,
		2026				2025
		Unaudited
Liabilities and shareholders' equity
Current liabilities:
Trade payables		$	256			$	610
Operating lease liabilities			894				814
Accrued liabilities and other payables			1,336				1,248
Total current liabilities			2,486				2,672
Non-current liabilities:
Operating lease liabilities			1,766				2,032
Total non-current liabilities			1,766				2,032
Total liabilities			4,252				4,704
Commitments and contingencies
Shareholders' Equity:
Ordinary shares, NIS 1.5 par value - authorized: 3,000,000 ordinary shares as of June 30, 2026 (unaudited) and December 31, 2025; issued and outstanding: 1,444,350 and 1,280,301 ordinary shares as of June 30, 2026 (unaudited) and December 31, 2025, respectively(*)			6,265				5,492
Additional paid in capital			128,311				126,397
Accumulated other comprehensive loss			(969)				(969)
Accumulated deficit			(130,662)				(124,839)
Total shareholders' equity			2,945				6,081
Total liabilities and shareholders' equity		$	7,197			$	10,785
(*) Adjusted to reflect the one-for-ten reverse share split effective September 4, 2026.

 

 

COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except share and per share data) (Unaudited)
		Six months ended June 30								Three months ended June 30
		2026				2025				2026				2025
Revenues		$	181			$	2,234			$	108			$	179
Cost of revenues			880				374				564				186
Gross profit (loss)			(699)				1,860				(456)				(7)
Operating expenses:
Research and development			2,843				4,118				1,165				2,013
General, administrative and marketing			2,206				2,568				1,012				1,158
Total operating loss			5,748				4,826				2,633				3,178
Financial income (expenses), net			(75)				27				(93)				(169)
Net loss for the period		$	(5,823)			$	(4,799)			$	(2,726)			$	(3,347)
Basic and diluted net loss per ordinary share (*)		$	(4.13)			$	(4.12)			$	(1.89)			$	(2.83)
Weighted average ordinary shares outstanding used in computation of basic and diluted net loss per share (*)			1,408,861				1,164,660				1,442,626				1,184,083
(*) Adjusted to reflect the one-for-ten reverse share split effective September 4, 2026.

 

 

COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in thousands) (Unaudited)
		Six months ended June 30,
		2026				2025
Cash flows from operating activities:
Net loss		$	(5,823)			$	(4,799)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			407				473
Loss from disposal of property and equipment			30				-
Accrued interest			(8)				(7)
Share-based compensation to employees and consultants			345				735
Exchange differences on cash and cash equivalents			(35)				(71)
Changes in assets and liabilities:
Decrease (increase) in trade receivables			(15)				150
Decrease (increase) in inventories			36				(111)
Decrease (increase) in other accounts receivable and prepaid expenses			(166)				69
Decrease in operating lease right of use assets			345				325
Increase (decrease) in trade payables			(354)				(299)
Decrease in operating lease liabilities			(232)				(112)
Increase (decrease) in accrued liabilities and other payables			88				40
Net cash used in operating activities			(5,382)				(3,607)
Cash flows from investing activities:
Purchase of property and equipment			(75)				(12)
Proceeds from sale of property and equipment			83				1
Net cash provided by (used in) investing activities			8				(11)
Cash flows from financing activities:
Proceeds from issuance of shares and warrants less issuance expenses			1,719				3,102
Proceeds on account of shares yet to be issued, net of issuance costs			620				-
Net cash provided by financing activities			2,339				3,102
Effect of exchange rate changes on cash and cash equivalents			3				41
Net decrease in cash and cash equivalents			(3,032)				(475)
Cash and cash equivalents at the beginning of the period			5,591				11,909
Cash and cash equivalents at the end of the period		$	2,559			$	11,434

 

 

COLLPLANT BIOTECHNOLOGIES LTD. APPENDICES TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in thousands) (Unaudited)
		Six months ended June 30,
		2026				2025
Supplemental disclosure of non-cash activities:
Right of use assets recognized with corresponding lease liabilities		$	46			$	58
Capitalization of Share-based compensation to inventory		$	3			$	2

 

 

COLLPLANT BIOTECHNOLOGIES LTD. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (U.S. dollars in thousands, except per share data) (Unaudited)
		Six months ended June 30								Three months ended June 30
		2026				2025				2026				2025
GAAP operating expenses:		$	5,049			$	6,686			$	2,177			$	3,171
Change of operating lease accounts			63				9				39				5
Share-based compensation to employees, directors and consultants			(345)				(735)				(165)				(353)
Non-GAAP operating expenses:			4,767				5,960				2,051				2,823
GAAP operating loss			(5,748)				(4,826)				(2,633)				(3,178)
Change of operating lease accounts			(63)				(9)				(39)				(5)
Share-based compensation to employees, directors and consultants			345				735				165				353
Non-GAAP operating loss			(5,466)				(4,100)				(2,507)				(2,830)
GAAP Net loss			(5,823)				(4,799)				(2,726)				(3,347)
Change of operating lease accounts			113				213				119				273
Share-based compensation to employees, directors and consultants			345				735				165				353
Non-GAAP Net loss		$	(5,365)			$	(3,851)			$	(2,442)			$	(2,721)
GAAP basic and diluted loss per ordinary share		$	(4.13)			$	(4.12)			$	(1.89)			$	(2.83)
NON- GAAP basic and diluted loss per ordinary share		$	(3.81)			$	(3.31)			$	(1.69)			$	(2.30)

 

About CollPlant

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is an innovative technology company operating at the intersection of deep-tech computing and advanced biotechnology. Through its subsidiary LightSolver, CollPlant is advancing the development of proprietary all-optical laser based computing architectures designed to resolve the world's most demanding computational bottlenecks across artificial intelligence, aerospace, financial engineering, and high-performance computing. Concurrently, CollPlant remains a leader in regenerative medicine, pioneering plant-derived recombinant human collagen (rhCollagen) technologies for 3D bioprinting of tissues and organs and medical aesthetics.

For more information about CollPlant, visit http://www.collplant.com. 

Use of Non-US GAAP ("non-GAAP")

Financial results for 2026 and 2025 are presented on both a GAAP and a non-GAAP basis. GAAP results were prepared in accordance with U.S. GAAP and include all revenue and expenses recognized during the period. The release contains certain non-GAAP financial measures for operating costs and expenses, operating income (or loss), net income (or loss) and basic and diluted net income (or loss) per share that exclude the effects of non-cash expense for share-based compensation to employees, directors and consultants, and change in operating lease accounts. CollPlant's management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance that enhances management's and investors' ability to evaluate the Company's operating costs, net income (or loss) and income (or loss) per share, and to compare them to historical Company results.

The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company's business internally and therefore decided to make these non-GAAP adjustments available to investors. The non-GAAP financial measures used by the Company in this press release may be different from the measures used by other companies.

The Company's condensed consolidated financial statements for the six months ended June 30, 2026, are presented in accordance with generally accepted accounting principles in the U.S.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements relating to the integration of LightSolver and the anticipated benefits of the acquisition; the development, commercialization and market adoption of LightSolver's LPU technology; the development and commercialization of CollPlant's rhCollagen-based products and product candidates; strategic collaborations; and the Company's future business and prospects. These statements can be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "may," "should," "could," "might," "seek," "target," "will," "project," "continue" and similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company's control. Factors that could cause actual results to differ materially include the risk that the anticipated benefits of the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver's business, operations and personnel; LightSolver's ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver's technology; the ability to develop and commercialize LightSolver's products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant's ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Contacts

CollPlant:

Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-reports-2026-second-quarter-financial-results-and-provides-corporate-update-302895046.html

SOURCE CollPlant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were CollPlant's second-quarter 2026 revenue and net loss?

CollPlant reported $108,000 in revenue and a $2.726 million GAAP net loss for the quarter ended June 30, 2026. Revenue was $179,000 and net loss was $3.347 million in the comparable 2025 quarter. Basic and diluted loss per ordinary share was $1.89, compared with $2.83.

When did CollPlant complete the LightSolver acquisition?

CollPlant completed its acquisition of LightSolver in September 2026, adding a laser-based photonic computing business. The acquisition was signed and completed after June 30, so LightSolver's operations are not included in CollPlant's reported second-quarter or first-half 2026 financial results.

What was CollPlant's September 2026 reverse share split ratio and effective date?

CollPlant's one-for-ten reverse share split took effect on September 4, 2026. The share counts and per-share figures in the financial tables were adjusted to reflect that split.

Who joined CollPlant's board following the LightSolver acquisition?

Dr. Ruti Ben Shlomi, LightSolver's CEO and co-founder, joined CollPlant's board following the acquisition's closing. The appointment supports the group's diversified commercial and technological roadmap.